Twenty genetic loci associating with nephrolithiasis were identified, 10 of which were initially identified from the UK Biobank discovery cohort (Supplementary Table 5) and another 10 from a subsequent trans-ethnic meta-analysis with Japanese GWAS summary statistics (Table 1 Table   7) 15 .
hypercalciuria, respectively 3, 6 and a strong family history of urolithiasis, including a parent and a sibling, results in a standard incidence ratio (SIR) for stone formation of >50 in contrast to a SIR of 1.29 in spouses 7 . Three genome-wide association studies of nephrolithiasis have been published, identifying six loci associated with disease [8] [9] [10] .
However, only two loci (CLDN14 and RGS14-SLC34A1) have been replicated and no trans-ethnic studies have been undertaken. To increase understanding of the common genetic factors contributing to risk of nephrolithiasis, genome-wide association studies and meta-analysis were undertaken using UK Biobank and Biobank Japan resources 11, 12 , integrating data from 12,123 stone formers and 416,928 controls.
Twenty genetic loci associating with nephrolithiasis were identified, 10 of which were initially identified from the UK Biobank discovery cohort (Supplementary Table 5) and another 10 from a subsequent trans-ethnic meta-analysis with Japanese GWAS summary statistics (Table 1 , Fig. 1 , and Supplementary Fig. 1 ) 13 . Fifty-four candidate genes were identified via in silico analysis of these 20 loci based on FUMA positional mapping, functional annotation, and biological plausibility 14 . MAGMA gene-property analysis implemented in FUMA revealed a striking overexpression of these genes in the kidney cortex; the GENE2FUNC tool demonstrated enrichment for gene ontologies associated with transmembrane ion transport, renal function, and calcium homeostasis, including "response to vitamin D" (Supplementary Fig. 2-3 and Table   7 ) 15 .
Population Attributable Risk (PAR) was calculated at each locus using data from the UK Biobank population, and ranged from 1.3% to 22.3% (Supplementary Table 6 ), indicating the importance of these variants in the pathogenesis of nephrolithiasis at a population level. The highest PAR was identified with a CYP24A1-associated locus and five of the identified loci, with PAR scores between 5.9-7.9%, were predicted to influence CaSR-signaling. These loci were selected for further analysis.
rs17216707 is ~38kb upstream of CYP24A1, a gene encoding cytochrome P450
family 24 subfamily A member 1 (CYP24A1), an enzyme that metabolises active 1,25-dihydroxyvitamin D to inactive 24,25-dihydroxyvitamin D. Loss-of-function mutations in CYP24A1 cause autosomal recessive infantile hypercalcaemia type 1 (OMIM 126065) 16 . We postulated that the CYP24A1 increased-risk allele associates with decreased CYP24A1 activity, leading to perturbations of calcium homeostasis and mimicking an attenuated form of infantile hypercalcaemia type 1. Therefore, associations of rs17216707 with serum calcium, phosphate, parathyroid hormone (PTH), and 25-hydroxyvitamin D concentrations, and urinary calcium excretion, and number of kidney stone episodes were sought in a validation cohort of kidney stone formers. 1,25-hydroxyvitamin D levels were unavailable. Reference ranges for 24-hour urinary calcium excretion differ for men and women 17 , thus associations with urinary calcium excretion were therefore examined separately.
Individuals homozygous for the CYP24A1 increased-risk allele rs17216707 (T) had a significantly increased mean serum calcium concentration when compared to heterozygotes, consistent with a recessive effect (mean serum calcium 2.36mmol/l (TT) vs. 2.32mmol/l (TC)) ( 
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OR>1 indicative of increased risk with effect allele. T-tests were used for comparisons between groups of parametric data, Mann-Whitney-U tests were used for comparison of non-parametric data (number of stone episodes).
Anova tests was used for comparisons of multiple sets of parametric data, no significance was reached. Kruskall-Wallis tests were used for comparisons of multiple sets of nonparametric data (number of stone episodes), significance at p=0.0024 was reached for CYP24A1 locus correlations. *Denotes significance on comparison to bold cohort within group at Bonferroni corrected threshold of p<0.05/7 = 0.007. §Normal ranges are from Nesbit Table 3 ).
Japanese patients: Diagnosis of nephrolithiasis was confirmed by enrolling physicians;
patients with bladder stones were excluded. DNA samples of 5,587 nephrolithiasis patients were obtained from BioBank Japan Validation cohort: DNA was extracted from whole blood samples using the Maxwell 16
Tissue DNA purification kit (Promega). SNP genotyping was undertaken using TaqMan SNP Genotyping Assays (ThermoFisher) and Type-it® Fast SNP Probe PCR Kit (Qiagen).
Quality Control
UK Biobank: Quality Control (QC) was performed using PLINK 10 v1.9 and R v3.3.1. All
SNPs with a call rate <90% were removed, accounting for the two different genotyping platforms used to genotype the individuals. Sample-level QC was undertaken and individuals excluded with one or more of the following: (1) call rate <98%, (2) Table 2 ). Subsequent case ascertainment was performed using the list of ICD-10 and OPCS codes for kidney and ureteric stones (Supplementary Figure 2) .
In order to gain insight into the biological pathways implicated by the FUMA-prioritised genes, a gene set analysis was implemented using the GENE2FUNC tool in FUMA using Figure 3) .
Population Attributable Risk
To assess the impact of an identified allele of interest from the meta-analysis with risk of kidney stone disease within the UK Biobank population, Population Attributable Risk 
Genotype-Phenotype Correlations
Associations were sought between genotype and serum calcium (albumin adjusted), phosphate, parathyroid hormone, and 25-hydroxyvitamin D, and urinary calcium excretion and number of stone episodes. Patients were excluded from inclusion in genotypephenotype correlations if they were known to have a disorder of calcium homeostasis, malabsorption, or other condition known to predispose to kidney stone disease.
Functional characterisation of the Calcium-Sensing Receptor Pathway
Cell culture and transfection. Functional studies were undertaken using HEK293 cells that Western blot analyses were undertaken using anti-DGKD (SAB1300472; Sigma), antiCaSR (5C10, ADD; ab19347; Abcam), and anti-PGK1 (ab154613; Abcam). The western blots were visualized using an Immuno-Star Western C kit (Bio-Rad) on a Bio-Rad
Chemidoc XRS+ system and relative expression of DGKD was quantified by denistometry using ImageJ software.
Compounds: Cinacalcet (AMG-073 HCL) was obtained from Cambridge Bioscience 
Statistics
For genotype-phenotype correlations, 2-tailed Student T Tests were used for parametric data. Mann-Whitney-U tests were used for comparison of non-parametric data (number of stone episodes). Anova tests were used for comparisons of multiple sets of parametric data.
Kruskall-Wallis tests were used for comparisons of multiple sets of non-parametric data (number of stone episodes). Significance was defined as p<0.05 after Bonferroni correction for 7 tests on each set of data, thus p<0.05/7=0.007.
For in vitro studies statistical comparisons were made with 2-tailed Student T Tests and maximal responses were compared using the F-test 25 .
